Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by JLGeminion May 27, 2010 10:45pm
318 Views
Post# 17138830

RE: RE: RE: RE: RE: RE: Date Clarification

RE: RE: RE: RE: RE: RE: Date ClarificationSharkfood, I was referring to the 2 Oct 2009 announcement of the SPA.  The November 2008 announcement was that they were applying for a pivotal trial on head & neck cancers.  The reality is that getting approval for bringing a virus into a hospital setting will only happen if there is no effective alternative treatment beyond palliative care.  I took the conference call as announcing that they stumbled onto their wedge case.  They did not have to continue demonstrating the merits of Reolysin with more phase I & II trials.  Face the facts; Oncolytics has treated more than 300 patients in trials with an outbreak.  The timeline reflects the challenge.  The SPA and Bayesian approach reflects the urgency of getting Reolysin to market.
Bullboard Posts